Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Inventory (2021 - 2025)

Historic Inventory for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to $22.1 million.

  • Rhythm Pharmaceuticals' Inventory rose 5910.04% to $22.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.1 million, marking a year-over-year increase of 5910.04%. This contributed to the annual value of $18.7 million for FY2024, which is 11731.22% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Inventory is $22.1 million, which was up 5910.04% from $18.9 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Inventory's 5-year high stood at $22.1 million during Q3 2025, with a 5-year trough of $111000.0 in Q4 2021.
  • In the last 5 years, Rhythm Pharmaceuticals' Inventory had a median value of $8.6 million in 2023 and averaged $11.1 million.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Inventory skyrocketed by 252792.79% in 2022, and later soared by 5503.92% in 2024.
  • Quarter analysis of 5 years shows Rhythm Pharmaceuticals' Inventory stood at $111000.0 in 2021, then soared by 2527.93% to $2.9 million in 2022, then soared by 195.65% to $8.6 million in 2023, then surged by 117.31% to $18.7 million in 2024, then rose by 17.96% to $22.1 million in 2025.
  • Its last three reported values are $22.1 million in Q3 2025, $18.9 million for Q2 2025, and $19.3 million during Q1 2025.